{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:15:46Z","timestamp":1761956146698,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1053\/j.seminhematol.2009.01.008","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T04:48:57Z","timestamp":1238647737000},"page":"S11-S15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S3","title":["Clinical Strategies to Achieve an Early and Successful Response to Tyrosine Kinase Inhibitor Therapy"],"prefix":"10.1053","volume":"46","author":[{"given":"Timothy","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2009.01.008_bib1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib5","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. In press."},{"key":"10.1053\/j.seminhematol.2009.01.008_bib6","doi-asserted-by":"crossref","first-page":"16a","DOI":"10.1182\/blood.V110.11.27.27","article-title":"Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy","volume":"110","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib7","doi-asserted-by":"crossref","first-page":"131a","DOI":"10.1182\/blood.V108.11.430.430","article-title":"Increasing frequency and marked stability of complete molecular response is observed in imatinib-treated CML patients with long-term follow up","volume":"108","author":"Branford","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib8","first-page":"182a","article-title":"Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase","volume":"102","author":"Druker","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib9","doi-asserted-by":"crossref","first-page":"345s","DOI":"10.1200\/jco.2006.24.18_suppl.6535","article-title":"High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up","volume":"24","author":"Aoki","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib10","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.01.008_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"A prospective study of imatinib 400 mg vs 800 mg as a front-line therapy in Sokal high risk Ph+ chronic myeloid leukemia patients","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2009.01.008_bib12","first-page":"160","article-title":"First report of the TOPS study: a randomized phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints","volume":"93","author":"Cortes","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib13","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib14","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib15","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib16","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib18","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib19","first-page":"317a","article-title":"Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.008_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"year":"2009","series-title":"NCCN: Clinical practice guidelines in oncology","key":"10.1053\/j.seminhematol.2009.01.008_bib23"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:19:10Z","timestamp":1758521950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196309000195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":23,"alternative-id":["S0037196309000195"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Strategies to Achieve an Early and Successful Response to Tyrosine Kinase Inhibitor Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}